Telomir (TELO) CEO Aminov issued 7,319,710 shares in TELI acquisition

Rhea-AI Filing Summary

Telomir Pharmaceuticals CEO and Chairman Erez Aminov reported a restructuring-related share exchange rather than an open-market trade. He is shown with 7,319,710 shares of common stock at a reported value of $1.3700 per share following the transaction. A footnote explains these Telomir shares were issued to him in exchange for his shares of TELI Pharmaceuticals, Inc. in connection with Telomir’s acquisition of TELI, so the filing reflects how his prior TELI ownership converted into Telomir equity.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Aminov Erez

Role CEO and Chairman

Type	Security	Shares	Price	Value
Other	Common Stock	7,319,710	$1.37	$10.03M

Holdings After Transaction: Common Stock — 7,319,710 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restructuring shares: 7,319,710 shares Price per share: $1.3700 per share Shares after transaction: 7,319,710 shares

3 metrics

Restructuring shares 7,319,710 shares Common stock tied to restructuring transaction code J

Price per share $1.3700 per share Reported transaction price for the 7,319,710 common shares

Shares after transaction 7,319,710 shares Total Telomir common stock held directly by CEO after Form 4 transaction

Key Terms

Other acquisition or disposition, restructuring, TELI Pharmaceuticals, Inc., Form 4

4 terms

Other acquisition or disposition financial

"transaction_code_description: "Other acquisition or disposition""

restructuring financial

"transactionSummary shows restructuringCount 1 and restructuringShares 7,319,710"

Restructuring is a deliberate rearrangement of a company’s operations, finances, or ownership—like reorganizing a cluttered house to run more efficiently—often involving cost cuts, asset sales, debt changes, or staff moves. Investors pay attention because restructuring can improve profitability and free up cash, but it can also signal distress, incur one-time costs, or dilute shareholder value; its success affects future earnings and stock performance.

TELI Pharmaceuticals, Inc. financial

"footnote references the Reporting Person's shares of TELI Pharmaceuticals, Inc."

Form 4 regulatory

"INSIDER FILING DATA (Form 4) for Telomir Pharmaceuticals, Inc."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aminov Erez

(Last) (First) (Middle)

C/O TELOMIR PHARMACEUTICALS, INC.

100 SE 2ND ST, SUITE 200 #1009

(Street)

MIAMI FLORIDA 33131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Telomir Pharmaceuticals, Inc. [ TELO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	04/22/2026	04/22/2026	J(1)		7,319,710	A	$1.37(1)	7,319,710	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock, no par value of the Issuer issued to the Reporting Person are in exchange for the Reporting Person's shares of TELI Pharmaceuticals, Inc. ("TELI") in connection with the Issuer's acquisition of TELI.

	/s/ Erez Aminov	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Telomir (TELO) report for CEO Erez Aminov?

Telomir reported a Form 4 for CEO Erez Aminov showing 7,319,710 common shares tied to an “other acquisition or disposition” restructuring. A footnote explains these Telomir shares were issued in exchange for his TELI Pharmaceuticals, Inc. shares in Telomir’s acquisition of TELI.

How many Telomir (TELO) shares does CEO Erez Aminov hold after this Form 4?

After the reported transaction, CEO Erez Aminov holds 7,319,710 shares of Telomir common stock directly. This entire amount is associated with a restructuring entry, reflecting shares received for his prior TELI Pharmaceuticals, Inc. holdings in Telomir’s acquisition of TELI.

Was the Telomir (TELO) CEO Form 4 an open-market buy or sell?

The Form 4 for Telomir’s CEO was not an open-market buy or sell. It is coded as transaction type J, an “other acquisition or disposition,” tied to a restructuring where Telomir shares were exchanged for his TELI Pharmaceuticals, Inc. shares in the acquisition.

What price per share is reported in the Telomir (TELO) CEO’s Form 4?

The Form 4 lists a transaction price of $1.3700 per Telomir common share. This price is attached to 7,319,710 shares involved in the restructuring‑type transaction related to exchanging TELI Pharmaceuticals, Inc. shares in Telomir’s acquisition of TELI.

How is the Telomir (TELO) CEO’s transaction categorized in the Form 4 summary?

The transaction is categorized as an “other transaction” with code J, counted in restructuring activity. The summary shows one restructuring event involving 7,319,710 shares, with no open-market buys, sells, gifts, tax withholdings, or derivative exercises reported for this Form 4.